叢琳
[摘要] 目的 研究大劑量干擾素輔助治療口腔黏膜惡性黑色素瘤的臨床效果,探討治療應(yīng)用的安全性。 方法 選取我院于2017年11月~2018年11月收治的80例口腔黏膜惡性黑色素瘤患者作為研究對(duì)象,按照治療方法不同分為兩組,每組40例。對(duì)照組患者僅采用單純手術(shù)治療,治療組在此基礎(chǔ)上采用大劑量干擾素輔助治療。觀察兩組患者生存情況、疾病復(fù)發(fā)情況以及毒副反應(yīng)。 結(jié)果 治療組患者生存期限及無(wú)復(fù)發(fā)生存期明顯長(zhǎng)于對(duì)照組,治療組復(fù)發(fā)率為5.00%,明顯低于對(duì)照組的22.50%,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。兩組患者毒副反應(yīng)比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。 結(jié)論 口腔黏膜惡性黑色素瘤患者予以大劑量干擾素輔助療法安全有效,值得臨床推廣。
[關(guān)鍵詞] 口腔黏膜;惡性黑色素瘤;干擾素;治療效果;安全性;臨床研究
[中圖分類號(hào)] R739.8? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] B? ? ? ? ? [文章編號(hào)] 1673-9701(2020)08-0065-03
Effect and safety of high-dose interferon in the treatment of malignant melanoma of oral mucosa
CONG Lin
Department of Stomatology, Jiamusi Central Hospital in Heilongjiang Province, Jiamusi? ?154002, China
[Abstract] Objective To study the clinical effect of high-dose interferon in the treatment of malignant melanoma of oral mucosa and to explore the safety of therapeutic application. Methods Eighty patients with oral mucosal malignant melanoma admitted to our hospital from November 2017 to November 2018 were enrolled in this study. They were divided into two groups according to different treatment methods, with 40 cases in each group. The patients in the control group were treated with surgery alone, and the treatment group was treated with high-dose interferon based on the above treatment. The survival, recurrence and side effects of the two groups were observed. Results The survival period and recurrence-free survival of the treatment group were significantly longer than those of the control group. The recurrence rate in the treatment group(5.00%) was significantly lower than that of the control group(22.50%), and the difference was statistically significant(P<0.05). There was no significant difference in toxicity between the two groups(P>0.05). Conclusion High-dose interferon adjuvant therapy for patients with oral mucosal malignant melanoma is safe and effective. It is worthy of clinical promotion.
[Key words] Oral mucosa; Malignant melanoma; Interferon; Therapeutic effect; Safety; Clinical research
黑色素瘤作為臨床上較為常見的惡性腫瘤,多見于患者皮膚、葡萄膜與黏膜[1],惡性程度極高,嚴(yán)重威脅著患者的生命健康[2]。黏膜惡性黑色素瘤屬于特殊的亞型,與皮膚惡性黑色素瘤相比,其惡性程度更高,預(yù)后較差[3]。因惡性黑色素瘤極容易與其他疾病混淆,所以大多數(shù)患者在確診后生命岌岌可危。單純手術(shù)治療惡性黑色素瘤預(yù)后較差,且口腔黏膜血供及淋巴引流充足,術(shù)后復(fù)發(fā)、病情轉(zhuǎn)移以及預(yù)后差等情況時(shí)有發(fā)生,本研究對(duì)手術(shù)治療患者采用大劑量α干擾素予以輔助,以探討其臨床療效?;诖耍x取我院于2017年11月~2018年11月期間收治的80例口腔黏膜惡性黑色素瘤患者,按照是否采用大劑量干擾素輔助治療分為兩組,比較兩組患者臨床療效及治療安全性?,F(xiàn)報(bào)道如下。
1 資料與方法
1.1 一般資料
選取我院于2017年11月~2018年11月收治的80例口腔黏膜惡性黑色素瘤患者,按照治療方法不同分為兩組,每組40例。治療組男22例,女18例;年齡24~79歲,平均(46.17±8.23)歲;腫瘤部位:下顎21例,牙齦19例。對(duì)照組男23例,女17例;年齡22~81歲,平均(47.09±7.24)歲;腫瘤部位:下顎24例,牙齦16例。兩組患者臨床資料比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05),具有可比性。納入標(biāo)準(zhǔn)[4]:①原發(fā)腭部及上頜牙齦黏膜,無(wú)治療史;②按照AJCC2000皮膚MM分期標(biāo)準(zhǔn)均為Ⅱ期或Ⅲ期;③每3個(gè)月能入院復(fù)診;④所有患者及其家屬均簽署知情同意書,同意本次研究。排除標(biāo)準(zhǔn)[5]:①肝腎功能不全及嚴(yán)重臟器疾病者;②血常規(guī)異常者;③不同意本次研究且失訪者。
[7] 陶文杰,韓永,周榕,等. 口腔黏膜黑色素瘤人源性移植瘤模型的建立及鑒定[J]. 中國(guó)口腔頜面外科雜志,2017,15(6):481-487.
[8] 劉暉. 口腔黏膜惡性黑色素瘤60例療效分析[J]. 現(xiàn)代中西醫(yī)結(jié)合雜志,2013,22(27):2992-2993.
[9] Song H,Jing G,Wang L,et al. Periodic acid -Schiff-positive loops and networks as a prognostic factor in oral mucosal melanoma[J]. Melanoma Res,2016,26(2):145-152.
[10] Kee D,Mcarthur G. Targeted therapies for cutaneous melanoma[J]. Hematol Oncol Clin North Am,2014,28(3):491-505.
[11] Wang X,Wu HM,Ren GX,et al. Primary Oral mucosal melano-ma:Advocate a wait-and-see policy in the clinically no patient[J]. J Oral Maxillofac Surg,2012,70(5):1192-1198.
[12] 王潤(rùn)湘,吳云騰,李朝軍,等.大劑量干擾素輔助治療國(guó)人口腔粘膜惡性黑色素瘤的臨床研究[J]. 臨床腫瘤學(xué)雜志,2014,19(4):318-322.
[13] 楊曉靜,孟瑋,徐宏俊,等. 長(zhǎng)鏈非編碼BANCR通過激活Wnt/β-catenin 信號(hào)通路調(diào)控黑色素瘤細(xì)胞遷移和侵襲行為[J]. 中國(guó)免疫學(xué)雜志,2018,34(1):50-54.
[14] Tripp MK,Watson M,Balk SJ,et al. State of the science on prevention and screening to reduce melanoma incidence and mortality:The time is now[J]. CA Cancer J Clin,2016,66(6):460-480.
[15] 張軼. 大劑量干擾素輔助治療口腔黏膜惡性黑色素瘤的效果及安全性研究[J]. 中外醫(yī)學(xué)研究,2018,16(33):172-173.
[16] Huang XL,Chen LL,Zhang L. Effects of paternal skin-to-skin contact in newborns and fathers after cesarean delivery[J]. The Journal of Perinatal & Neonatal Nursing,2019, 33(1):68.
[17] Abdelaal NK,Ellakwa HE,Elhalaby AF,et al. Scalpel versus diathermy skin incision in caesarean section[J]. Journal of Obstetrics and Gynaecology,2019,39(3):340.
(收稿日期:2019-10-09)